References
- Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995; 311: 899–909.
- Cullen MH, Billingham LJ, Woodroffe CM et al. Mitomycin, ifosfamide and cisplatin in unresectable non-small cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999; 17: 3188–3194.
- Huisman C, Smit EF, Giaccone G, Postmus PE. Second-line chemotherapy in relapsing or refractory non-small cell lung cancer: a review. J Clin Oncol 2000; 18: 3722–3730.
- Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003. J Clin Oncol 2004; 22: 330–353.
- Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095–2103.
- Fossella FV, De Vore R, Kerr RN et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000; 18: 2354–2362.
- Smit E, Mattson K, von Pawel J et al. Alimta (peme-trexed disodium) as second line treatment of non-small cell lung cancer: a phase II study. Ann Oncol 2003; 14: 455–460.
- Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemothera-py. J Clin Oncol 2004; 22: 1589–1597.
- Fukuoka M, Yano S, Giaccone G et al. Multi-Institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21: 2237–2246.
- Kris MG, Natale RB, Herbst RS et al. Efficacy of gefi-tinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290 (16): 2149–2158.
- Shepherd FA, Pereira J, Ciuleanu TE et al. A random-ized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of first line or second line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. Proc Am Soc Clin Oncol 2004; 23 (abstract No 7022).